Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept in JIA subtypes (CLIPPER)
NCT00962741Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2009
- Primary completion
- Jun 2011
- Modality
- Fc-Fusion Proteins
- Countries
- 19
01
Overview
A Phase 3 trial of etanercept in extended oligoarticular juvenile idiopathic arthritis (EOJIA), enthesitis-related juvenile idiopathic arthritis (ERA), psoriatic arthritis (PsA), sponsored by Pfizer. Started Sep 2009; status: completed.
02
Drugs
etanercept
03
Conditions
extended oligoarticular juvenile idiopathic arthritis (EOJIA)enthesitis-related juvenile idiopathic arthritis (ERA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT00962741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00962741.